Table 3.
Non-adjusted hazard ratios (HRs) with 95% confidence intervals (CI) of disease-specific and overall mortality of pancreatic ductal adenocarcinoma patients based on number of T cells (low and high). Results of whole sections and hotspots are presented separately
| Number of patients | Low HR (95% CI) |
High HR (95% CI) |
|
|---|---|---|---|
| Whole sections | |||
| Disease-specific mortality | |||
| CD3 core (crude) | 79 | 1.00 (Reference) | 0.35 (0.13–0.98) |
| CD3 front (crude) | 79 | 1.00 (Reference) | 0.18 (0.39–1.20) |
| CD8 core (crude) | 79 | 1.00 (Reference) | 0.83 (0.47–1.46) |
| CD8 front (crude) | 79 | 1.00 (Reference) | 0.46 (0.26–0.81) |
| Overall mortality | |||
| CD3 core (crude) | 79 | 1.00 (Reference) | 0.42 (0.17–1.06) |
| CD3 front (crude) | 79 | 1.00 (Reference) | 0.72 (0.42–1.23) |
| CD8 core (crude) | 79 | 1.00 (Reference) | 0.88 (0.51–1.52) |
| CD8 front (crude) | 79 | 1.00 (Reference) | 0.52 (0.30–0.90) |
| Hotspots | |||
| Disease-specific mortality | |||
| CD3 core (crude) | 79 | 1.00 (Reference) | 0.67 (0.36–1.23) |
| CD3 front (crude) | 79 | 1.00 (Reference) | 0.56 (0.29–1.08) |
| CD8 core (crude) | 79 | 1.00 (Reference) | 0.89 (0.47–1.70) |
| CD8 front (crude) | 79 | 1.00 (Reference) | 0.80 (0.46–1.42) |
| Overall mortality | |||
| CD3 core (crude) | 79 | 1.00 (Reference) | 0.74 (0.41–1.32) |
| CD3 front (crude) | 79 | 1.00 (Reference) | 0.65 (0.35–1.19) |
| CD8 core (crude) | 70 | 1.00 (Reference) | 0.91 (0.49–1.71) |
| CD8 front (crude) | 70 | 1.00 (Reference) | 0.92 (0.53–1.59) |